It promotes brain metabolism and improves brain circulation by reducing cerebrovascular resistance and increasing cerebral blood flow. In addition, it can enhance the function of the ascending activation system of the brainstem reticular formation, enhance the function of the pyramidal system, improve motor paralysis, and play a certain role in promoting the recovery of brain function and awakening.

This product is a medium-acting anticoagulant of the dicoumarin class. Its mechanism of action is to competitively counteract the effect of vitamin K, inhibit the synthesis of coagulation factors in hepatocytes, and also has the effect of reducing thrombin-induced platelet aggregation reaction, thus having anticoagulant and antiplatelet aggregation functions.

Extract from the above information

Docetaxel is a taxane that promotes the assembly of microtubule dimers into microtubules and stabilizes microtubules by preventing the depolymerization process, thereby blocking cells in the G2 and M phases and inhibiting the mitosis and proliferation of cancer cells. Its pharmacological effect is stronger than that of paclitaxel, with an intracellular concentration three times higher than that of paclitaxel, a longer intracellular retention time, and an affinity for microtubules that is twice that of paclitaxel; as a microtubule stabilizer and assembly promoter, its activity is twice that of paclitaxel; as a microtubule depolymerization inhibitor, its activity is twice that of paclitaxel. In in vitro antitumor activity tests, it has been confirmed that the antitumor activity of docetaxel is 1.3 to 12 times that of paclitaxel. Clinical studies have shown that docetaxel has a higher efficacy than paclitaxel for anthracycline-resistant breast cancer. Docetaxel is the most effective drug for the second-line treatment of anthracycline-resistant breast cancer so far; in monotherapy and combination chemotherapy for non-small cell lung cancer, docetaxel is one of the most effective drugs.

Docetaxel is a taxane that promotes the assembly of microtubule dimers into microtubules and stabilizes microtubules by preventing the depolymerization process, thereby blocking cells in the G2 and M phases and inhibiting the mitosis and proliferation of cancer cells. Its pharmacological effect is stronger than that of paclitaxel, with an intracellular concentration three times higher than that of paclitaxel, a longer intracellular retention time, and an affinity for microtubules that is twice that of paclitaxel; as a microtubule stabilizer and assembly promoter, its activity is twice that of paclitaxel; as a microtubule depolymerization inhibitor, its activity is twice that of paclitaxel. In in vitro antitumor activity tests, it has been confirmed that the antitumor activity of docetaxel is 1.3 to 12 times that of paclitaxel. Clinical studies have shown that docetaxel has a higher efficacy than paclitaxel for anthracycline-resistant breast cancer. Docetaxel is the most effective drug for the second-line treatment of anthracycline-resistant breast cancer so far; in monotherapy and combination chemotherapy for non-small cell lung cancer, docetaxel is one of the most effective drugs.